Genetic Signatures (ASX:GSS) EBIT per Share : A$-0.14 (TTM As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures EBIT per Share?

Genetic Signatures's EBIT per Share for the six months ended in Jun. 2024 was A$-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.14.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Genetic Signatures's EBIT per Share or its related term are showing as below:

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Genetic Signatures was 8.70% per year. The lowest was -38.10% per year. And the median was 4.05% per year.

ASX:GSS's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.05
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Genetic Signatures's EBIT for the six months ended in Jun. 2024 was A$-10.23 Mil.

Genetic Signatures EBIT per Share Historical Data

The historical data trend for Genetic Signatures's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures EBIT per Share Chart

Genetic Signatures Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EBIT per Share

Get a 7-Day Free Trial

-0.02

0.01

0.02

-0.10

-0.14

Genetic Signatures Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial														-0.01	-0.05	-0.05	-0.08	-0.06

Genetic Signatures EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Genetic Signatures's EBIT per Share for the fiscal year that ended in Jun. 2024 is calculated as

	EBIT per Share		(A: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-22.333	/	165.264
=	-0.14

Genetic Signatures's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.232	/	186.616
=	-0.05

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.14

Genetic Signatures (ASX:GSS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Genetic Signatures EBIT per Share Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Signatures Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042

Website

https://www.geneticsignatures.com

Genetic Signatures Ltd is a specialist molecular diagnostics company, specialising in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are primarily based in Australia, with sales and support teams in the UK, Germany, and the United States.